Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$17.15 - $28.31 $23.7 Million - $39.2 Million
-1,384,293 Closed
0 $0
Q4 2021

Feb 08, 2022

BUY
$19.35 - $28.41 $10.3 Million - $15.1 Million
532,987 Added 62.61%
1,384,293 $39.3 Million
Q3 2021

Nov 12, 2021

BUY
$16.88 - $25.23 $14.4 Million - $21.5 Million
851,306 New
851,306 $17.9 Million

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.94B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Frazier Management LLC Portfolio

Follow Frazier Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Frazier Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Frazier Management LLC with notifications on news.